Regeneron, Roche injectable antibody drug shows efficacy in preventing Covid-19
A Regeneron Pharmaceuticals antibody cocktail currently authorized for treating Covid-19 now has additional clinical data showing it reduces the risk of infection spread. The drug developer, along with partner Roche, plan to ask regulators to expand the drug’s authorization to include disease prevention.
Shares0
A Covid-19 antibody cocktail developed by Regeneron Pharmaceuticals and Roche has pivotal clinical trial data showing it protected against the spread of infection among people in the same household. The results support use of the drug as a preventative measure in a formulation that’s easier for both physicians and patients.
Kintara Therapeutics Inc says interim Phase 2 study data on VAL-083 shows its potential as game-changing treatment option for GBM patients
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
NA Proactive news snapshot: Fury Gold Mines Limited, INDVR Brands Inc, Aurania Resources Ltd, Alternus Energy Group PLC …
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
MedCity News
Microsoft builds out cloud healthcare business with $19.7B Nuance acquisition
Microsoft will buy up healthcare AI partner Nuance for $19.7 billion. Nuance makes speech-recognition tools for clinical documentation, as well as security tools.
Shares0
Nuance’s Dragon Ambient eXperience system is installed in a clinic. The voice recognition system automatically populates clinicians’ notes. Photo credit: Nuance
Microsoft is acquiring voice recognition company Nuance Communications as it competes with other cloud companies for a share of the healthcare market.
It plans to buy the company for a total of $19.7 billion in an-all cash deal, including Nuance’s debt. The deal was priced at $56 per share, up 23% from Nuance’s closing price on Friday.